Glioblastoma cellular cross-talk converges on NF-κB to attenuate EGFR inhibitor sensitivity

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Glioblastoma (GBM) exhibits heterogeneous expression of epidermal growth factor receptor (EGFR) and its mutant form, EGFRvIII.
• This heterogeneity poses a significant challenge for EGFR-targeted therapies.

Purpose of the Study:

• To elucidate the mechanism by which heterogeneous EGFR expression limits sensitivity to EGFR tyrosine kinase inhibitors (TKIs).
• To identify potential therapeutic strategies to overcome resistance in GBM.

Main Methods:

• Investigated interclonal communication mediated by interleukin-6 (IL-6) in EGFRvIII-positive GBM cells.
• Examined the role of the NF-κB signaling axis and bromodomain protein 4 (BRD4) in survivin (BIRC5) expression.
• Assessed the impact of inhibiting IL-6, NF-κB, BRD4, or survivin on TKI sensitivity in vitro and in vivo.

Main Results:

• EGFRvIII-positive cells secrete IL-6, which activates NF-κB signaling in a paracrine and autocrine manner.
• IL-6 signaling promotes BRD4-dependent survivin expression, leading to reduced sensitivity to EGFR TKIs.
• NF-κB and survivin are coordinately upregulated in GBM patient tumors.
• Inhibition of NF-κB, survivin, or BRD4 restored sensitivity to EGFR TKIs in preclinical models.

Conclusions:

• Intratumoral heterogeneity creates an interclonal communication circuitry involving IL-6, NF-κB, and survivin that confers resistance to EGFR TKIs.
• Targeting this NF-κB-mediated survival pathway represents a promising strategy to enhance the efficacy of anti-EGFR therapies in GBM.